Navigation Links
Rheumatoid Arthritis Drugs Price Analysis and Strategies 2012-2016 & Forecasts to 2021 -Research and Markets
Date:2/28/2017

DUBLIN, Feb 28, 2017 /PRNewswire/ --


Research and Markets has announced the addition of the "Rheumatoid Arthritis Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Rheumatoid Arthritis Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Rheumatoid Arthritis market.

The research answers the following questions:

  • What are the key drugs marketed for Rheumatoid Arthritis and their clinical attributes? How are they positioned in the Global Rheumatoid Arthritis market?
  • What are the unit prices and annual treatment cost for Rheumatoid Arthritis therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Rheumatoid Arthritis drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Rheumatoid Arthritis?

Research Scope:

  • Rheumatoid Arthritis Treatment Options - Identify key drugs marketed and prescribed for Rheumatoid Arthritis in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Rheumatoid Arthritis Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Rheumatoid Arthritis
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Rheumatoid Arthritis market
  • Rheumatoid Arthritis Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Rheumatoid Arthritis in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Rheumatoid Arthritis New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Rheumatoid Arthritis are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Rheumatoid Arthritis drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Rheumatoid Arthritis market
  • Identify the effective pricing for a new drug

For more information about this report visit http://www.researchandmarkets.com/research/vjsw3w/rheumatoid

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rheumatoid-arthritis-drugs-price-analysis-and-strategies-2012-2016--forecasts-to-2021--research-and-markets-300414740.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost
2. Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis
3. U.S. and European Rheumatologists Agree That a Therapys Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis
4. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
5. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
6. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
7. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
8. Hospira Shares Results From Two Open-label Extension Studies for Biosimilar Infliximab in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis
9. Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
10. Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis
11. Global Rheumatoid Arthritis Drugs Market 2014-2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... 2017 ... coming to Washington DC ... Tuesday, September 12 th – Monday, September 18 th .The Brain ... MRI brain scans to the public.Where:  BTF,s Mobile ... 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road ...
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... -- For nearly two decades, New Life Agency has been committed to providing ... New Life Agency announces a powerful three-way partnership designed to deliver substantial ... ... http://www.schrafts2.com/ ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... ... technology-enabled services supporting clinical research, today announces that 30 of its domain ... the drug development lifecycle at upcoming industry conferences and webinars. Drawing on ...
(Date:9/25/2017)... ... September 25, 2017 , ... Earlypicker is expanding its offerings ... shop for the hottest Korean cosmetics and fashion trends sweeping the nation. The decision ... already well-known for the great offerings that allow Koreans everywhere to look their best ...
(Date:9/25/2017)... , ... September 25, 2017 , ... “The Majestic Unicorn”: ... the great flood. “The Majestic Unicorn” is the creation of published author, Dayna Chantel, ... small, came from far and wide to march aboard the cypress ark-vessel. Male and ...
(Date:9/25/2017)... Philadelphia, PA (PRWEB) , ... September 25, 2017 , ... Emerald Ash Borers ... pest's destruction can be seen throughout the Philadelphia region. A video by Rob Nagy, ... is lined with Ash trees. While several are dead or showing signs of decline ...
(Date:9/24/2017)... ... ... Throughout the United States and the world, clinicians take a simple but ... providers work to give the best care possible to patients and communities, while seeking ... are threatening to tie our hands in carrying out that oath. The Graham-Cassidy legislation ...
Breaking Medicine News(10 mins):